ArticleInternational urology and nephrology2025
Varieties of altered TFE3 can occur in MiT-family-related renal cell carcinomas.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Series of renal cell carcinomas with TFE3 overexpression by copy number gains and without TFE3 gene rearrangement.Virchows Archiv : an international journal of pathology · 2025Article
- TFE3-rearranged renal cell car cinoma with massive calcification: Imaging-pathologic correlation.Journal of clinical imaging science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn TFE3 translocation renal cell carcinoma (RCC), rearrangements involving the TFE3 gene can lead to overexpression of the TFE3 transcription factor. This upregulation increases lysosomal activity and autophagy, which in turn contributes to tumor cell proliferation. Although TFE3 translocation RCC is one of the more extensively studied RCC subtypes, other genetic abnormalities, such as gene copy number alterations, may also play a role in disease development. Accordingly, this study aimed to more precisely categorize TFE3-altered RCC variants using fluorescence in situ hybridization (FISH), while also evaluating their histopathological characteristics and clinical behavior.
methodsIn this retrospective study spanning the past 9 years, 16 cases of renal cell carcinoma (RCC) were examined for TFE3 gene alterations using FISH. The cohort was divided into two groups: TFE3-altered RCC cases as the positive group (n = 6) and TFE3-negative RCC cases as the negative group (n = 10). TFE3 alterations, tumor pathology, and clinical outcomes were systematically evaluated.
resultsThe age of patients with TFE3-altered RCC ranged from 6 to 70 years old. There were five female patients and one male patient, which is consistent with the known female predominance of this RCC subtype. The TFE3 alterations observed in this cohort included: TFE3 gene rearrangement (n = 1), TFE3 gene rearrangement with copy number gain (n = 1), copy number gain of intact TFE3 gene (n = 3), and copy number loss of TFE3 gene (n = 1). Clinical outcomes varied, with some patients experiencing poor prognoses, including the development of distant metastases.
conclusionsOur data show that TFE3 alterations in RCC span a range of genetic events, from gene rearrangements to copy number variations, as determined by FISH. These TFE3-altered RCCs in adults may be associated with unfavorable outcomes, underscoring the value of FISH in both diagnosing and refining our understanding of TFE3-altered RCC.
Indexed as
Identifiers
39966236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.